Head-to-head evidence
Cerebrolysin vs MLC901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Multi-target (ginsenoside) · full Alzheimer's Disease pipeline
Cerebrolysin
Developed by EVER Neuro Pharma (EVER Pharma)
NCT00911807 · Phase 2 · completed
This was a randomized, quadruple-blinded, three-arm trial with 217 patients, comparing Cerebrolysin plus donepezil, Cerebrolysin alone, and donepezil alone. The primary endpoint, change in ADAS-Cog+ at week 28, did not show a statistically significant difference among the groups (overall p=0.6348; pairwise comparisons all non-significant), so the study did not meet its primary cognitive endpoint. Although the design was strong, the null primary result limits the evidence to a moderate level.
MLC901 · NeuroAiD II
Developed by Moleac Pte Ltd
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2029 · NCT07191028 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cerebrolysin's landscape · MLC901's landscape